BUD vs SPRY
BUD (BUD) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
BUD does not have a complete income-statement cache yet.
Latest reported SPRY revenue for 2026-06-30 was $56.3M. Net income was -$123.0M. SPRY currently screens at market cap $983.1M.
BUD currently screens at market cap $0. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the BUD and SPRY stock pages for the full models.
Not investment advice.